2023 World Conference on Lung Cancer (Posters)-EP03.03. Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS CoV2 Vaccination in Patients with Non Small Cell Lung Cancer

EP03.03. Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS CoV2 Vaccination in Patients with Non Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

The study examined the impact of tyrosine kinase inhibitors (TKIs) on the immune response to SARS-CoV-2 vaccination in patients with non-small cell lung cancer (NSCLC). The research aimed to understand the influence of targeted therapy on immune protection derived from COVID-19 vaccination. Blood samples were collected from 92 NSCLC patients and 27 healthy individuals after receiving a COVID-19 vaccine. Serum and mononuclear cells were isolated and analyzed to measure SARS-CoV-2 antibodies and characterize B-cell subpopulations.<br /><br />The results showed that NSCLC patients may have impaired protection from the SARS-CoV-2 vaccine due to immune dysregulation caused by the underlying malignant disease and its treatment. Antibody synthesis by B-cells plays a significant role in controlling and clearing the SARS-CoV-2 virus. However, limited information is available about the influence of targeted therapy on immune protection post-vaccination.<br /><br />The study found reduced antibody titers against SARS-CoV-2 and lower levels of antigen-secreting cells in NSCLC patients with EGFR mutations undergoing TKIs. This suggests that TKIs may impair antibody production and B-cell activity in NSCLC patients.<br /><br />The clinical characteristics of the study population were also analyzed. No significant differences were observed in gender, age, COVID-19 status, SARS-CoV-2 vaccine types received, EGFR mutations, ALK alterations, or TKI treatment between healthy individuals and NSCLC patients. However, lower spike-antibody levels were found in NSCLC patients with EGFR mutations or ALK alterations undergoing TKIs compared to healthy individuals.<br /><br />In conclusion, the study highlights that the immune response to SARS-CoV-2 vaccination may be compromised in NSCLC patients undergoing targeted therapy. TKIs, specifically in patients with EGFR mutations, were found to reduce antibody production and B-cell activity. Further research is needed to better understand the impact of targeted therapy on immune protection in cancer patients post-vaccination.

Asset Subtitle

Norma Hernández Pedro

Meta Tag

Speaker Norma Hernández Pedro

Topic Tumor Biology: Translational Biology - IO

Keywords

tyrosine kinase inhibitors

immune response

SARS-CoV-2 vaccination

non-small cell lung cancer

targeted therapy

COVID-19 vaccine

antibody synthesis

B-cell subpopulations

EGFR mutations

ALK alterations